Phaseline

Companies › Santhera Pharmaceuticals

Santhera Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Neurology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
vamorolone
Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist
NR3C1, NR3C2Phase 4Duchenne Muscular DystrophySep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06713135vamorolonePhase 4Duchenne Muscular DystrophyNeurologySep 2028

Targets

NR3C1 (1) NR3C2 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Laboratorios Sophia S.A de C.V. Optinose US Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.